Lv3
272 积分 2022-07-30 加入
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1小时前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
1小时前
已完结
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
1小时前
已完结
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
2小时前
已完结
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
2小时前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
2小时前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2小时前
已完结
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
2小时前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2小时前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
2天前
已完结
皖公网安备34019202002308
